Low risk of severe COVID-19 in patients with inflammatory bowel disease: keep calm and take stock

Mariangela Allocca1,2, Vincenzo Craviotto1

1 Humanitas Clinical and Research Center – IRCCS, Rozzano, Italy
2 Department of Biomedical Sciences, Humanitas University, Pieve Emanuele, Italy

The global SARS-CoV-2 pandemic has hugely impacted healthcare systems worldwide. In the last year, numerous efforts were made to understand how the virus behaves, which population is at higher risk of hospitalization, intensive care support, and death, and how the immune system interacts with SARS-CoV-2. In the field of immune-mediated disease, and, in particular, management of inflammatory bowel disease (IBD), there is still ongoing concern about the susceptibility of patients with IBD to SARS-CoV-2 infection and its impact on their outcomes. According to anthropometric, clinical, and pharmacological characteristics, the stratification of the risk of contracting the infection and developing severe disease (COVID-19) needs further investigation. Considering the high number of patients treated with disease-modifying drugs, deemed at increased risk of severe infections including opportunistic infections caused by viral, bacterial, parasitic, and fungal agents, it is a challenging issue for experts in the field.

In this issue of Polish Archives of Internal Medicine (Pol Arch Intern Med), Łodyga et al1 report data from a multicenter, prospective, observational study assessing the seroprevalence of anti-SARS-CoV-2 antibodies in Polish patients with IBD. The authors noted a higher percentage of patients with SARS-CoV-2 infection (diagnosed by positive results of anti-SARS-CoV-2 antibodies) among those with IBD as compared with a control group of non-IBD healthcare professionals (4.6% vs 1.6%). At the same time, however, no symptomatic COVID-19 was observed in that IBD cohort. Moreover, the authors did not find any association between seroprevalence rates and the type of IBD or ongoing medication.

Coronaviruses bind to angiotensin-converting enzyme 2, which is constitutively expressed by the epithelial cells of the lung, intestine, kidney, and blood vessels. The second step is the fusion of the coronavirus envelope with the host cell membrane, which is activated through proteolytic cleavage induced by host cell trypsin-like proteases. Both angiotensin-converting enzyme 2 and trypsin-like proteases are upregulated in the inflamed gut of patients with IBD, suggesting that they may be at increased risk of SARS-CoV-2 infection, as shown in the study by Łodyga et al2. Previous studies assessing SARS-CoV-2 seroprevalence in patients with IBD treated with biologic therapy reported highly variable data, ranging from 21% to 2.3%, but in any case comparable to that of the control groups.3,4 A key feature of COVID-19-related acute respiratory distress syndrome is the activation of the immune system characterized by a cytokine storm. Biological therapy may play a protective or therapeutic role against the cytokine storm triggered by SARS-CoV-2 and may even suggest that some cytokine blockers may have reduced the risk of COVID-19 in the study population investigated by Łodyga et al,2 although their patients with IBD showed a higher frequency of having contact with SARS-CoV-2.

The evidence available until now suggests that patients with IBD do not have an increased incidence of COVID-19,6-8 and biologic therapy, such as treatment with monoclonal antibodies, does not represent a risk factor for a more severe course of COVID-19.9-11 Since March 2020, the International Organization for the Study of Inflammatory Bowel Disease has set up an international registry, Surveillance Epidemiology of Coronavirus Under Research Exclusion (SECURE-IBD), to track all cases of COVID-19 among patients with IBD. It represents an additional tool that will be essential to provide insight into the impact of SARS-CoV-2 infection on patients with IBD, including the influence of...
factors such as age, comorbidities, and IBD treatments. Currently, there are about 5524 patients with IBD in the SECURE-IBD registry reported to be infected with SARS-CoV-2. The data available so far have been reassuring and show that patients with IBD are not at higher risk of developing severe COVID-19 compared with the general population. Further information from this relevant resource will soon be available to facilitate clinical management and, particularly, guide the use of medical therapy in patients with IBD during the pandemic.

To conclude, growing evidence demonstrates that patients with IBD are not at higher risk of a severe COVID-19 course. Anyway, patients with IBD should follow the same indications valid for the general population in order to minimize the risk of infection, whereas therapies can be continued without any concern about the susceptibility to COVID-19 in this group.

ARTICLE INFORMATION

DISCLAIMER The opinions expressed by the author(s) are not necessarily those of the journal editors, Polish Society of Internal Medicine, or publisher.

CONFLICT OF INTEREST MA received consulting fees from Nikkiso Europe, Mundipharma, Janssen, Abbvie, and Pfizer. VC has no conflicts of interest to declare.

OPEN ACCESS This is an Open Access article distributed under the terms of the Creative Commons Attribution-NonCommercial-ShareAlike 4.0 International License (CC BY-NC-SA 4.0), allowing third parties to copy and redistribute the material in any medium or format and to remix, transform, and build upon the material, provided the original work is properly cited, distributed under the same license, and used for noncommercial purposes only. For commercial use, please contact the journal office at pamw@mp.pl.

HOW TO CITE Allocca M, Craviotto V. Low risk of severe COVID-19 in patients with inflammatory bowel disease: keep calm and take stock. Pol Arch Intern Med. 2021; 131: 222-223. doi:10.20452/pamw.15903

REFERENCES
1. Rahier JF, Magro F, Abreu C, et al. Second European evidence-based consensus on the prevention, diagnosis and management of opportunistic infections in inflammatory bowel disease. J Crohns Colitis. 2014; 8: 443-468.
2. Łodyga M, Maciejewska K, Eder P, et al. Inflammatory bowel disease is associated with higher seroprevalence rates of antibodies against SARS-CoV-2. Pol Arch Intern Med. 2021; 131: 226-232.
3. Monteleone G, Ardizzone S. Are patients with inflammatory bowel disease at increased risk for Covid-19 infection? J Crohns Colitis. 2020; 14: 1334-1336.
4. Berte’ R, Maza S, Stefanucci MR, et al. Seroprevalence of SARS-CoV-2 in IBD patients treated with biologic therapy. J Crohns Colitis. 2020 Nov 19. [Epub ahead of print].
5. Norsa L, Cosimo P, Indriolo A, et al. Asymptomatic severe acute respiratory syndrome coronavirus 2 infection in patients with inflammatory bowel disease under biologic treatment. Gastroenterology. 2020; 159: 2229-2231.e2.
6. D’Amico F, Danese S, Peyrin-Biroulet L. Systematic review on inflammatory bowel disease patients with coronavirus disease 2019: it is time to take stock. Clin Gastroenterol Hepatol. 2020; 18: 2689-2700.
7. Allocca M, Chaparro M, Gonzales HA, et al. Patients with inflammatory bowel disease are not at increased risk of COVID-19: a large multinational cohort study. J Clin Med. 2020; 9: 3533.
8. Allocca M, Fiorino G, Zallot C, et al. Incidence and patterns of COVID-19 among inflammatory bowel disease patients from the Nancy and Milan cohorts. Clin Gastroenterol Hepatol. 2020; 18: 2134-2135.
9. Bezzio C, Saibeni S, Variola A, et al. Outcomes of COVID-19 in 79 patients with IBD in Italy: an IG-IBD study. Gut. 2020; 69: 1213-1217.
10. Brenner EJ, Ungaro RC, Geary RB, et al. Bowel diseases: results from an international registry. Gastroenterology. 2020; 159: 481-491.e3.
11. Allocca M, Guidelli GM, Borrini RG, et al. Clinical course of COVID-19 in 41 patients with immune-mediated inflammatory diseases: experience from Humanitas center, Milan. Pharmacol Res. 2020; 160: 105601.
12. Brenner EJ, Ungaro RC, Colombel JF. SECURE-IBD database public data update. https://covidibd.org/. Accessed March 9, 2021.